1: Haematologica. 2009 Jun 16. [Epub ahead of print] Links The anti-cancer drug, phenoxodiol, kills primary myeloid and lymphoid leukemic blasts and rapidly proliferating T cells.Herst PM, Davis JE, Neeson P, Berridge MV, Ritchie DS. Wellington, New Zealand.
Background The redox-active isoflavene anti-cancer drug, phenoxodiol, has previously been shown to inhibit plasma membrane electron transport and cell proliferation and promote apoptosis in a range of cancer cell lines and in anti-CD3/anti-CD28-activated murine splenocytes but not in non-transformed WI-38 cells and human umbilical vein endothelial cells. DESIGN AND METHODS: We determined the effects of phenoxodiol on plasma membrane electron transport, MTT responses and viability of activated and resting human T cells. In addition, we evaluated the effect of phenoxodiol on the viability of leukemic cell lines and primary myeloid and lymphoid leukemic blasts. RESULTS: We demonstrated that phenoxodiol inhibited plasma membrane electron transport and cell proliferation (IC(50) 46 muM and 5.4 muM, respectively) and promoted apoptosis of rapidly proliferating human T cells but did not affect resting T cells. Phenoxodiol also induced apoptosis in T cells stimulated in HLA-mismatched allogeneic mixed lymphocyte reactions. Conversely, non-proliferating T cells in the mixed lymphocyte reaction remained viable and could be restimulated in a third party mixed lymphocyte reaction, in the absence of phenoxodiol. In addition, we demonstrated that leukemic blasts from patients with primary acute myeloid leukemia (n=22) and acute lymphocytic leukemia (n=8) were sensitive to phenoxodiol. The lymphocytic leukemic blasts were more sensitive than the myeloid leukemic blasts to 10 muM phenoxodiol exposure for 24h (viability of 23+/-4% and 64+/-5%, respectively, p=0.0002). Conclusions The ability of phenoxodiol to kill rapidly proliferating lymphocytes makes this drug a promising candidate for the treatment of pathologically-activated lymphocytes such as those in acute lymphoid leukemia, or diseases driven by T-cell proliferation such as auto-immune diseases and graft-versus-host disease.
PMID: 19535345 [PubMed - as supplied by publisher]
Related articles The antiproliferative effects of phenoxodiol are associated with inhibition of plasma membrane electron transport in tumour cell lines and primary immune cells. Biochem Pharmacol. 2007 Dec 3; 74(11):1587-95. Epub 2007 Aug 19. [Biochem Pharmacol. 2007] [The role of intercellular adhesion molecule-1 in binding of acute myeloid leukemic blasts cells to human umbilical vein endothelial cells] Zhonghua Nei Ke Za Zhi. 2003 Jun; 42(6):413-6. [Zhonghua Nei Ke Za Zhi. 2003] Specific recognition of human leukemic cells by allogeneic T cell lines. Transplantation. 1989 Sep; 48(3):486-95. [Transplantation. 1989] ReviewRituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs. 2003; 63(8):803-43. [Drugs. 2003] Review[Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children.] Folia Med Cracov. 2001; 42(3):5-80. [Folia Med Cracov. 2001] » See reviews... | » See all... Recent Activity Clear Turn Off Turn On The antiproliferative effects of phenoxodiol are associated with inhibition of plasma memb...The antiproliferative effects of phenoxodiol are associated with inhibition of plasma membrane electron transport in tumour cell lines and primary immune cells.The anti-cancer drug, phenoxodiol, kills primary myeloid and lymphoid leukemic blasts and ...The anti-cancer drug, phenoxodiol, kills primary myeloid and lymphoid leukemic blasts and rapidly proliferating T cells.Your browsing activity is empty.
